Several therapeutic strategies to target CSCs have emerged, such as the development of a bispecific antibody that brings cytotoxic T cells to CD133+ CSCs in pancreatic and hepatic cancers and blockade of CD47 to target CSCs in leukemia. The gene discussed is PROM1; the disease is leukemia.